Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study

The treatment options for psoriasis in HIV-infected individuals are limited due to the immunosuppressive nature of the therapeutic modalities and the patient's immunocompromised state. Etanercept has been shown to be safe and effective in the non-HIV psoriasis population with nearly 20 years of...

Full description

Saved in:
Bibliographic Details
Published inJournal of drugs in dermatology Vol. 11; no. 3; p. 413
Main Authors Lee, Eric S, Heller, Misha M, Kamangar, Faranak, Park, Kelly K, Koo, John Y M
Format Journal Article
LanguageEnglish
Published United States 01.03.2012
Subjects
Adult
Etanercept
HIV Infections - complications
Humans
Immunoglobulin G - administration & dosage
Immunoglobulin G - adverse effects
Immunoglobulin G - therapeutic use
Immunologic Factors - administration & dosage
Immunologic Factors - adverse effects
Immunologic Factors - therapeutic use
Male
Psoriasis - drug therapy
Psoriasis - pathology
Receptors, Tumor Necrosis Factor - administration & dosage
Receptors, Tumor Necrosis Factor - therapeutic use
Severity of Illness Index
Time Factors
Online AccessGet more information

Cover

More Information
Summary:The treatment options for psoriasis in HIV-infected individuals are limited due to the immunosuppressive nature of the therapeutic modalities and the patient's immunocompromised state. Etanercept has been shown to be safe and effective in the non-HIV psoriasis population with nearly 20 years of experience. However, there is limited data on the safety of etanercept use in the HIV patient population. The authors report a case of an HIV-infected patient with psoriasis who has remained mostly clear on continuous, uninterrupted etanercept use for over six years.
ISSN:1545-9616